Abstract
Lung cancer is one of the most common malignant tumours worldwide and its high mortality rate makes it a leading cause of cancer-related deaths. To address this daunting challenge, we need a comprehensive understanding of the pathogenesis and progression of lung cancer in order to adopt more effective therapeutic strategies. In this regard, integrating multi-omics data of the lung provides a highly promising avenue. Multi-omics approaches such as genomics, transcriptomics, proteomics, and metabolomics have become key tools in the study of lung cancer. The application of these methods not only helps to resolve the immunotherapeutic mechanisms of lung cancer, but also provides a theoretical basis for the development of personalised treatment plans. By integrating multi-omics, we have gained a more comprehensive understanding of the process of lung cancer development and progression, and discovered potential immunotherapy targets. This review summarises the studies on multi-omics and immunology in lung cancer, and explores the application of these studies in early diagnosis, treatment selection and prognostic assessment of lung cancer, with the aim of providing more personalised and effective treatment options for lung cancer patients.
1 Introduction
Lung cancer has been one of the most common malignant tumours globally over the past decades. Despite the widespread use of conventional treatments such as surgery, radiotherapy, chemotherapy and targeted drug therapy, the five-year survival rate for lung cancer is usually less than 20% (1). Additionally, at all stages, less than 7% of patients survive more than ten years after diagnosis (2). In recent years, the emergence of immunotherapy has marked a revolution in cancer treatments, which not only has an acceptable safety profile, but also produces durable therapeutic responses in a wide range of patient populations (3). Nonetheless, lung cancer exhibits significant histological heterogeneity, diverse genomic profiles, and differential responses to therapy (4), and still poses significant challenges for immunotherapy and prevention.
With the rapid development of multi-omics technology, covering genomics, transcriptomics, proteomics and metabolomics, our understanding of lung cancer is deepening (5, 6). Multi-omics technology has constructed a progressive analysis framework from the genetic basis to the effect of environmental exposure (7), and has deeply analysed the pathogenesis, pathophysiological process and molecular basis of immunotherapy of lung cancer, which has provided a strong support for the scientific formulation of precise treatment strategies.
The aim of this review is to explore recent advances in multi-omics studies of lung cancer and their potential applications in early diagnosis, treatment selection and prognostic assessment. By integrating immunotherapy and multi-omics data in order to better understand the complex molecular network of lung cancer, it provides new ideas and methods for individualised treatment and precision medicine of lung cancer.
2 Lung cancer immunotherapy and genomics
Lung cancer, as a highly heterogeneous disease, has been profoundly influenced by molecular biology in its pathogenesis and therapeutic strategies. In non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), unique molecular features of different histological subtypes have been revealed through the identification of specific genetic variants and epigenetic modifications, thus providing new directions for individualised treatment of lung cancer.
In NSCLC, histological subtypes frequently dominated by lung adenocarcinoma (LUAD) and squamous cell carcinoma are common (8). The complexity of NSCLC is reflected in its variable genetic variants. Common target gene driver mutations include genes such as epidermal growth factor receptor (EGFR), KRAS, MET, BRAF, ALK, ROS proto-oncogene 1 (ROS1) and RET (9) (Figure 1A). Through combined whole exome sequencing (WES) technology, it was found that common mutations in LUAD include tumour suppressor genes TP53 (46%), STK11 (17%), KEAP1 (17%), NF1 (11%), RB1 (4%) and CDKN2A (4%), as well as chromatin modification genes SETD2 (9%), ARID1A (7%), SMARCA4 (6%) and RNA splicing genes RBM10 (8%) and U2AF1 (3%) (10). Mutations in the genes FGFR1, NRF2, AKT1 and DDR2 are particularly prominent in lung squamous cell carcinoma (10).
Figure 1
For SCLC, deep sequencing of key oncogenes by advanced integrated mutational profiling (MSK-IMPACT) technology (11) revealed inactivating mutations or deletion of tumour suppressor genes such as TP53, RB1, KMT2D, PTEN, NOTCH1, CREBBP, FAT1, NF1 and APC, and inactivating mutations in PIK3A, EGFR and KRAS activating mutations in oncogenes (12). Unlike NSCLC, SCLC is often accompanied by the expression of MYC oncogenes, which contribute to rapid cell proliferation and lead to DNA replication stress (13). In addition, epigenetic modifications play a key role in lung carcinogenesis, and heritable chromatin modifications such as DNA methylation, histone modifications, and non-coding RNA regulation regulate gene expression without altering the DNA sequence (9, 10, 14–16) (Figure 1A). Epigenetic mutations and disruptions are strongly associated with multiple tumour types, providing new ideas for targeted lung cancer therapy based on molecular subtype differences.
Genomics plays an important role in the classification, treatment and prognostic assessment of lung cancer. Traditionally, lung cancer classification was based on histological patterns, whereas advances in genomics have allowed lung cancer to be characterised also by tumour biomarkers and genetic alterations. For example, Stephen J Murphy et al. defined a common origin or lineage of lung cancer by analysing genomic rearrangements and somatic DNA linkages, and used these specific DNA linkages as precise tumour markers to differentiate between primary and metastatic lung cancer (17).
Genome sequencing technology has revealed key genetic variants in lung cancer, facilitating the development of personalised treatment strategies. The study noted that in non-small cell lung cancer (NSCLC), aberrant activation of the PI3K-AKT-mTOR pathway is closely associated with resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs), and that its activation is mainly caused by PIK3CA, AKT1 mutations and PTEN deletion. This discovery led to the development of drugs targeting mTOR (e.g., everolimus and temsirolimus) and EGFR-TKIs targeting EGFR and ALK (e.g., ositinib, gefitinib, ceritinib, and loratinib), which have demonstrated clinical efficacy in the treatment of lung cancer (18) (Table 1).
Table 1
| Modifiable targets | Therapeutic drug | Reference |
|---|---|---|
| EGFR | Osimertinib | (19) |
| Gefitinib | (20) | |
| Dacomitinib | (21) | |
| Erlotinib | (22) | |
| Afatinib | (23) | |
| Amivantamab | (24) | |
| ALK | Crizotinib | (25) |
| Ceritinib | (26) | |
| Alectinib | (27) | |
| Brigatinib | (28) | |
| Lorlatinib | (29) | |
| RET | Cabozantinib | (30) |
| Selpercatinib | (31) | |
| Pralsetinib | (32) | |
| ROS1 | Crizotinib | (33) |
| Entrectinib | (34) | |
| Lorlatinib | (35) | |
| MET | Glesatinib | (36) |
| BRAF V600E | Dabrafenib | (37) |
| Trametinib | (38) | |
| Vemurafenib | (39) | |
| KRAS | Adagrasib | (40) |
| Sotorasib (AMG 510) | (41) | |
| VEGFR | Bevacizumab | (42) |
| Ramucirumab | (43) |
Targeted therapeutics drugs and targets in a genomic perspective.
Immune checkpoint inhibitors (ICIs) have become key agents in tumour immunotherapy, especially in the treatment of lung cancer. However, their potential to cause immune-related adverse effects makes the search for biomarkers that predict response to ICI therapy crucial (9). Investigators assessed early predictors of anti-PD-L1 therapy by analysing circulating tumour DNA (ctDNA), and their study showed that a reduction in the frequency of the variant allele was associated with tumour shrinkage after 6 weeks of treatment, providing a valuable non-invasive method for predicting the effectiveness of treatment (44).
3 Lung cancer immunotherapy and transcriptomics
In the field of tumour immunotherapy, targeting the tumour microenvironment (TME) for precision medicine is one of the latest research directions. In this process, immune cells play a key role (45). Immune cell interactions are regulated by transcription factors and further contribute to the immune response. Wu et al. identified interactions between cancer cells and endothelial cells, fibroblasts, and macrophages by single-cell RNA sequencing analysis of NSCLC patient samples, revealing multiple signalling pathways (e.g., EGFR, NOTCH, WNT, and PDGF, etc.) that are associated with carcinogenesis (Figure 1B). These findings shed more light on the molecular interactions and immunoregulatory mechanisms of NSCLC and provide a new perspective on the treatment of lung cancer (46).
In TME, individual cells are precisely regulated by transcription factors. Through the regulation of transcription factors, the killing of cells can be modulated. ONECUT2 and ETV4 were found to be likely potential regulators of CD8 T cell depletion in the blood of NSCLC patients, whereas the transcription factors BACH1 and RUNX3 were up-regulated in CD8 T cytotoxic subpopulations. Thus, regulation of these transcription factors may drive cytotoxic immune responses in NSCLC (47). Immune cell macrophages (TAM) in TME are among the most common immunosuppressive cells. Increased TAM in TME has been associated with immunotherapy resistance by transcriptomic analysis, and its expression is regulated by genes such as CD27, ITGAM and CCL5 (48). Recent studies have shown that TAM interacts with carnitine palmitoyltransferase 1A (CPT1A), increasing resistance to iron death and inactivation of CD8 T cells in lung cancer. Therefore, the use of CPT1 inhibitors enhances the killing of tumour cells by chemotherapy or immunotherapy (49) (Figure 1B).
In the field of lung cancer treatment, transcriptomics is often combined with other histological approaches to extend its application. By combining transcriptomics and metabolomics, the researchers analysed the effects of AZD-6482 (a PI3Kβ-targeted inhibitor) on 28 metabolite-related genes in LUAD. They found that the expression of three genes, LDHA, PPAT, and SMS, was increased in untreated LUAD samples; whereas after treatment with AZD-6482, the expression of these genes was significantly decreased, suggesting that the inhibitor may improve the prognosis of LUAD patients (50). By joining forces with proteomics, Qing et al. used Cancer Cell Line Encyclopaedia (CCLE) RNA sequencing and proteomics profiles in human NSCLC cell lines to identify genes that are pan-sensitive and pan-resistant to drugs used in the treatment of NSCLC with systemic or targeted therapies (51).
4 Lung cancer immunotherapy and proteomics
With the rapid development of mass spectrometry (MS) technology, large-scale protein analysis has become a hotspot in scientific research, in which proteomics has achieved remarkable results in the study of protein phosphorylation, interaction, structure and function (52–55). In particular, proteomics has shown great potential for the discovery of new therapies and biomarkers. These biomarkers come from a wide range of sources, including body fluids and specific samples from lung cancer studies, such as breath condensate (56–59).
In the study of lung cancer proteomics, proteins in receptor tyrosine kinases such as EGFR and ALK and their downstream signalling pathways play a key role in the pathological process of lung cancer (60–62). EGFR, as a member of the ErbB family, promotes malignant cell survival, proliferation, etc. through a series of biochemical processes, making EGFR and its downstream signalling pathway an important target for lung cancer therapy.
In addition, the discovery of immune checkpoints (ICP) has led to a major breakthrough in the field of immunotherapy (63). In normal physiology, ICP maintains immune system homeostasis, but tumour cells evade immune attack by expressing ICP proteins (3). Among them, the interaction of programmed death receptor 1 (PD-1) with programmed cell death ligand-1 (PD-L1), cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and CD80/86 is the main mechanism of tumour cell escape (Figure 1C). Significant progress has been made in the development of targeted therapeutic agents for lung cancer against these immune checkpoint proteins (64). By blocking the function of these proteins, the immune system in the patient’s body is activated to recognize and attack tumour cells more effectively, bringing new therapeutic hope to lung cancer patients. Over the past decade, tyrosine kinase inhibitors (TKIs) have made significant advances in the treatment of cancer, especially NSCLC.EGFR-TKI, as a potent agent for the treatment of over-activation of EGFR signalling, has been developed for multiple generations with remarkable efficacy (54, 65).
In the development of the field of immunotherapy, it is particularly important to achieve selective destruction of tumours by activating the immune response of T cells (64, 65). PD-1/PD-L1 inhibitors in combination with chemotherapy have become the standard of care in advanced NSCLC (62, 66). In clinical study finds,PD-1 antibodies such as Nivolumab and Pembrolizumab demonstrate durable efficacy in a variety of cancers (67, 68) (Figure 1C). In addition, anti-CTLA-4 antibodies such as Lpilimumab and Tremelimumab play an important role in immunotherapy.
Immunotherapy has great potential in the field of cancer treatment, including checkpoint inhibitors, monoclonal antibodies, and over-the-counter cell transplantation (69). Scholars such as Wang and Chiu emphasized that the combination of multiple therapies is the key to enhancing the effectiveness of cancer treatment and is expected to significantly improve patient survival rates (70, 71).
5 Lung cancer immunotherapy and metabolomics
Metabolomics delves into metabolite changes in organisms, providing new insights into the pathology and drug mechanisms of lung cancer. By analysing lung cancer samples and identifying metabolic markers closely related to lung cancer, it brings new perspectives for early diagnosis, treatment planning and prognosis assessment (72–74).
In the oncogenic transformation of lung cancer cells, there are significant metabolic changes that are particularly dependent on energy sources such as ATP. Among these, the Warburg effect is particularly pronounced in lung cancer cells, where their metabolic needs are met by increased glucose uptake and support nucleotide and amino acid biosynthesis (75). SCLC is significantly dependent on exogenous arginine, which is associated with the deficiency or low expression of arginine succinyl synthase 1 (ASS1) (76, 77). The study found that up to 45% of SCLC samples and 50% of cell lines exhibited ASS1-negativity, highlighting the importance of arginine biosynthesis downregulation in the progression of lung carcinogenesis (78, 79).
The interaction between signalling and metabolism is critical in lung cancer research. mTOR kinases in the PI3K/Akt/mTOR pathway form the mTORC1 and mTORC2 complex, which influences protein, nucleotide, and lipid metabolism (80) (Figure 1D). MYC gene changes affect bioenergetic processes (81). Changes in metabolic state can also inversely regulate signalling pathway activity, e.g., mTORC1 activity is reduced during energy shortage (82).
Developing more effective lung cancer treatment regimens by modulating metabolic pathways or monitoring the disease using metabolic markers. In particular, lung cancer immunotherapy is closely linked to metabolomics, an important cornerstone of lung cancer treatment (83). The markers provided by metabolomics support personalized strategies for immunotherapy and improve treatment efficiency. In addition, the study by Ma et al. revealed the relationship between the regulation of amino acid metabolism, hypoxia-inducible factor-1 (HIF-1) and PI3K-Akt pathways and ositinib resistance, providing new perspectives for understanding the mechanism of drug resistance (84). These studies emphasize the critical role of metabolomics in monitoring marker changes after treatment (85).
For SCLC, polyethylene glycolated arginine deiminase (ADI-PEG20) and human recombinant polyethylene glycolated arginase (e.g., rhArgPEG, BCT-100, etc.) have been regarded as potential therapeutic targets due to arginine nutritional deficiency. And the combination of arginine with PD-1/PD-L1 inhibitors has also demonstrated efficacy in the clinic (76).
The combination of immunotherapy and metabolomics in lung cancer provides patients with more effective and personalized treatment options that are expected to improve their quality of life.
6 Discussion
In recent years, immunotherapies, particularly targeted therapies, have transformed the management and prognosis of lung cancer by providing personalized treatment options for lung cancer patients (86). And the integration of multi-omics data offers the unique advantage of aiming for a comprehensive assessment of each patient through extracted features, which promises a more complete picture of this complex immune ecosystem.
However, although ICI has been widely used in the treatment of lung cancer, there is still a lack of adequate understanding of prognostic biomarkers. We still need to increase research efforts on prognostic biomarkers for lung cancer at the multi-omics level such as proteomics and genomics. For example, genetic mutations in EGFR and KRAS have a key role in individualized therapy, but their specific impact and mechanisms in prognostic assessment need to be further explored (87, 88). In addition, proteomic markers such as CEA and CYFRA 21-1 show potential in disease surveillance, and their correlation with disease progression could provide additional information for disease management (89, 90).
Immune tolerance and therapeutic resistance are also current challenges in the combination of immunology and proteomics for the treatment of lung cancer. In particular, the EGFR T790M mutation leads to resistance to early drug (91–93). Specifically, although the third-generation EGFR-TKI ositinib has successfully treated patients with T790M mutations, new resistance mechanisms such as the EGFR T790M/C797S mutation are still emerging. Currently, there are investigators evaluating fourth-generation EGFR-TKIs clinically for new resistance issues (94, 95).
By integrating these multi-omics data, we can develop a more comprehensive understanding of the biological complexity of lung cancer, leading to the development of more effective therapeutic strategies and improved patient survival (96). Therefore, future research should focus on how to use these biomarkers to optimize treatment pathways, improve the accuracy of prognostic prediction, and ultimately achieve true precision medicine.
Statements
Author contributions
YY: Conceptualization, Data curation, Writing – original draft, Writing – review & editing. SS: Data curation, Writing – original draft. JML: Data curation, Writing – original draft. LS: Data curation, Writing – original draft. BW: Validation, Writing – original draft. JZ: Validation, Writing – original draft. JL: Validation, Writing – original draft. HL: Validation, Writing – original draft. PH: Validation, Writing – original draft. KX: Supervision, Writing – original draft. XS: Supervision, Writing – original draft. SH: Supervision, Writing – original draft.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This project is supported by the Doctoral Startup Fund of the Affiliated Hospital of Southwest Medical University (No. 19025), Innovation and Entrepreneurship Training Program of Southwest Medical University (No. 2023393), (Luzhou city- Southwest Medical University) Collaborative Application Foundation Project (No. 2023LZXNYDJ033).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
SungHFerlayJSiegelRLLaversanneMSoerjomataramIJemalAet al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2021) 71:209–49. doi: 10.3322/caac.21660
2
CrinòLWederWvan MeerbeeckJFelipE. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. (2010) 21 Suppl 5:v103–15. doi: 10.1093/annonc/mdq207
3
LahiriAMajiAPotdarPDSinghNParikhPBishtBet al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. (2023) 22:40. doi:Â 10.1186/s12943-023-01740-y
4
de SousaVMLCarvalhoL. Heterogeneity in lung cancer. Pathobiology. (2018) 85:96–107. doi: 10.1159/000487440
5
AlyassATurcotteMMeyreD. From big data analysis to personalized medicine for all: challenges and opportunities. BMC Med Genomics. (2015) 8:33. doi:Â 10.1186/s12920-015-0108-y
6
MaAMcDermaidAXuJChangYMaQ. Integrative methods and practical challenges for single-cell multi-omics. Trends Biotechnol. (2020) 38:1007–22. doi: 10.1016/j.tibtech.2020.02.013
7
Mohammadi-ShemiraniPSoodTParéG. From ‘Omics to multi-omics technologies: the discovery of novel causal mediators. Curr Atheroscler Rep. (2023) 25:55–65. doi: 10.1007/s11883-022-01078-8
8
ChenPLiuYWenYZhouC. Non-small cell lung cancer in China. Cancer Commun (Lond). (2022) 42:937–70. doi: 10.1002/cac2.v42.10
9
AbbasianMHArdekaniAMSobhaniNRoudiR. The role of genomics and proteomics in lung cancer early detection and treatment. Cancers (Basel). (2022) 14:5144–60. doi: 10.3390/cancers14205144
10
SallerJJBoyleTA. Molecular pathology of lung cancer. Cold Spring Harb Perspect Med. (2022) 12:369–77. doi: 10.1101/cshperspect.a037812
11
MacGregorGAMarkanduNDSmithSJSagnellaGA. Captopril: contrasting effects of adding hydrochlorothiazide, propranolol, or nifedipine. J Cardiovasc Pharmacol. (1985) 7 Suppl 1:S82–7. doi: 10.1097/00005344-198507001-00016
12
RudinCMBrambillaEFaivre-FinnCSageJ. Small-cell lung cancer. Nat Rev Dis Primers. (2021) 7:3. doi:Â 10.1038/s41572-020-00235-0
13
YuanMZhaoYArkenauH-TLaoTChuLXuQ. Signal pathways and precision therapy of small-cell lung cancer. Signal Transduct Target Ther. (2022) 7:187. doi:Â 10.1038/s41392-022-01013-y
14
KarpinetsTVFoyBD. Tumorigenesis: the adaptation of mammalian cells to sustained stress environment by epigenetic alterations and succeeding matched mutations. Carcinogenesis. (2005) 26:1323–34. doi: 10.1093/carcin/bgi079
15
AnsariJShackelfordREEl-OstaH. Epigenetics in non-small cell lung cancer: from basics to therapeutics. Transl Lung Cancer Res. (2016) 5:155–71. doi: 10.21037/tlcr.2016.02.02
16
BajboujKAl-AliARamakrishnanRKSaber-AyadMHamidQ. Histone modification in NSCLC: molecular mechanisms and therapeutic targets. Int J Mol Sci. (2021) 22:11701. doi:Â 10.3390/ijms222111701
17
MurphySJHarrisFRKosariFBarreto Siqueira Parrilha TerraSNasirAJohnsonSHet al. Using genomics to differentiate multiple primaries from metastatic lung cancer. J Thorac Oncol. (2019) 14:1567–82. doi: 10.1016/j.jtho.2019.05.008
18
HamouzMHammouzRYBajwaMAAlsayedAWOrzechowskaMBednarekAK. A functional genomics review of non-small-cell lung cancer in never smokers. Int J Mol Sci. (2023) 24:13314. doi:Â 10.3390/ijms241713314
19
RoperNBrownA-LWeiJSPackSTrindadeCKimCet al. Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer. Cell Rep Med. (2020) 1:100007. doi:Â 10.1016/j.xcrm.2020.100007
20
LiuS-YBaoHWangQMaoW-MChenYTongXet al. Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes. Nat Commun. (2021) 12:6450. doi:Â 10.1038/s41467-021-26806-7
21
HouBLuXGaoD-CLiuQ-XZhouDZhengHet al. REPORT- Clinical outcomes of using second - versus first-Generation EGFR-tkis for the First-Line treatment of advanced NSCLC patients with EGFR mutations: A meta-analysis. Pak J Pharm Sci. (2021) 34:1459–68.
22
MaHTianXZengX-TZhangYWangYWangFet al. The efficacy of erlotinib versus conventional chemotherapy for advanced nonsmall-cell lung cancer: A PRISMA-compliant systematic review with meta-regression and meta-analysis. Med (Baltimore). (2016) 95:e2495. doi:Â 10.1097/MD.0000000000002495
23
YangJCHSequistLVGeaterSLTsaiC-MMokTSKSchulerMet al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. (2015) 16:830–8. doi: 10.1016/S1470-2045(15)00026-1
24
ZhouCTangK-JChoBCLiuBPaz-AresLChengSet al. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. N Engl J Med. (2023) 389:2039–51. doi: 10.1056/NEJMoa2306441
25
SolomonBJBauerTMMokTSKLiuGMazieresJde MarinisFet al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. (2023) 11:354–66. doi: 10.1016/S2213-2600(22)00437-4
26
SoriaJ-CTanDSWChiariRWuY-LPaz-AresLWolfJet al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. (2017) 389:917–29. doi: 10.1016/S0140-6736(17)30123-X
27
WuY-LDziadziuszkoRAhnJSBarlesiFNishioMLeeDHet al. Alectinib in resected ALK-positive non-small-cell lung cancer. N Engl J Med. (2024) 390:1265–76. doi: 10.1056/NEJMoa2310532
28
CamidgeDRKimHRAhnM-JYangJC-HHanJ-YLeeJ-Set al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. (2018) 379:2027–39. doi: 10.1056/NEJMoa1810171
29
SolomonBJBauerTMIgnatius OuS-HLiuGHayashiHBearzAet al. Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase III CROWN study. J Clin Oncol. (2022) 40:3593–602. doi: 10.1200/JCO.21.02278
30
DrilonARekhtmanNArcilaMWangLNiAAlbanoMet al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol. (2016) 17:1653–60. doi: 10.1016/S1470-2045(16)30562-9
31
DrilonAOxnardGRTanDSWLoongHHFJohnsonMGainorJet al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med. (2020) 383:813–24. doi: 10.1056/NEJMoa2005653
32
GainorJFCuriglianoGKimD-WLeeDHBesseBBaikCSet al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. (2021) 22:959–69. doi: 10.1016/S1470-2045(21)00247-3
33
ShawATOuS-HIBangY-JCamidgeDRSolomonBJSalgiaRet al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. (2014) 371:1963–71. doi: 10.1056/NEJMoa1406766
34
DesaiAVRobinsonGWGauvainKBasuEMMacyMEMaeseLet al. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol. (2022) 24:1776–89. doi: 10.1093/neuonc/noac087
35
ShawATSolomonBJChiariRRielyGJBesseBSooRAet al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. (2019) 20:1691–701. doi: 10.1016/S1470-2045(19)30655-2
36
EngstromLDArandaRLeeMTovarEAEssenburgCJMadajZet al. Glesatinib exhibits antitumor activity in lung cancer models and patients harboring MET exon 14 mutations and overcomes mutation-mediated resistance to type I MET inhibitors in nonclinical models. Clin Cancer Res. (2017) 23:6661–72. doi: 10.1158/1078-0432.CCR-17-1192
37
PlanchardDKimTMMazieresJQuoixERielyGBarlesiFet al. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol. (2016) 17:642–50. doi: 10.1016/S1470-2045(16)00077-2
38
BouffetEGeoergerBMoertelCWhitlockJAAertsIHargraveDet al. Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric BRAF V600-mutant low-grade glioma. J Clin Oncol. (2023) 41:664–74. doi: 10.1200/JCO.22.01000
39
HymanDMPuzanovISubbiahVFarisJEChauIBlayJ-Yet al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. (2015) 373:726–36. doi: 10.1056/NEJMoa1502309
40
SkoulidisFGoldbergMEGreenawaltDMHellmannMDAwadMMGainorJFet al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. (2018) 8:822–35. doi: 10.1158/2159-8290.CD-18-0099
41
CanonJRexKSaikiAYMohrCCookeKBagalDet al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. (2019) 575:217–23. doi: 10.1038/s41586-019-1694-1
42
PatelJDSocinskiMAGaronEBReynoldsCHSpigelDROlsenMRet al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. (2013) 31:4349–57. doi: 10.1200/JCO.2012.47.9626
43
GaronEBCiuleanuT-EArrietaOPrabhashKSyrigosKNGokselTet al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. (2014) 384:665–73. doi: 10.1016/S0140-6736(14)60845-X
44
RajaRKuzioraMBrohawnPZHiggsBWGuptaADennisPAet al. Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab. Clin Cancer Res. (2018) 24:6212–22. doi: 10.1158/1078-0432.CCR-18-0386
45
ZhangPWuXWangDZhangMZhangBZhangZ. Unraveling the role of low-density lipoprotein-related genes in lung adenocarcinoma: Insights into tumor microenvironment and clinical prognosis. Environ Toxicol. (2024) 24:6212–22. doi: 10.1002/tox.24230
46
WuFFanJHeYXiongAYuJLiYet al. Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nat Commun. (2021) 12:2540. doi:Â 10.1038/s41467-021-22801-0
47
ZhaoYZhangQTuKChenYPengYNiYet al. Single-cell transcriptomics of immune cells reveal diversity and exhaustion signatures in non-small-cell lung cancer. Front Immunol. (2022) 13:854724. doi:Â 10.3389/fimmu.2022.854724
48
LarroquetteMGueganJ-PBesseBCousinSBrunetMLe MoulecSet al. Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies. J Immunother Cancer. (2022) 10:e003890. doi:Â 10.1136/jitc-2021-003890
49
MaLChenCZhaoCLiTMaLJiangJet al. Targeting carnitine palmitoyl transferase 1A (CPT1A) induces ferroptosis and synergizes with immunotherapy in lung cancer. Signal Transduct Target Ther. (2024) 9:64. doi:Â 10.1038/s41392-024-01772-w
50
ThaiparambilJDongJGrimmSLPereraDAmbatiCSRPutluriVet al. Integrative metabolomics and transcriptomics analysis reveals novel therapeutic vulnerabilities in lung cancer. Cancer Med. (2023) 12:584–96. doi: 10.1002/cam4.v12.1
51
YeQHickeyJSummersKFalatovichBGenchevaMEubankTDet al. Multi-omics immune interaction networks in lung cancer tumorigenesis, proliferation, and survival. Int J Mol Sci. (2022) 23:14978. doi:Â 10.3390/ijms232314978
52
ChenFChandrashekarDSVaramballySCreightonC.A.-O.X. Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. Nat Commun. (2019) 10(1):5679. doi:Â 10.1038/s41467-019-13528-0
53
HanashSTaguchiA. Application of proteomics to cancer early detection. Cancer J. (2011) 17(6):423–8. doi: 10.1097/PPO.0b013e3182383cab
54
MoonmuangSA-OTantraworasinAA-OOrrapinSUdomrukSChewaskulyongBPruksakornDet al. The role of proteomics and phosphoproteomics in the discovery of therapeutic targets and biomarkers in acquired EGFR-TKI-resistant non-small cell lung cancer. Int J Mol Sci. (2023) 24(5):4827. doi:Â 10.3390/ijms24054827
55
ZhangPZhangHTangJRenQZhangJChiHet al. The integrated single-cell analysis developed an immunogenic cell death signature to predict lung adenocarcinoma prognosis and immunotherapy. Aging (Albany NY). (2023) 15:10305–29. doi: 10.18632/aging.205077
56
TyersMMannM. From genomics to proteomics. Nature. (2003) 422(6928):193–7. doi: 10.1038/nature01510
57
ZhouLBeuermanRW. The power of tears: how tear proteomics research could revolutionize the clinic. Expert Rev Proteomics. (2017) 14(3):189–91. doi: 10.1080/14789450.2017.1285703
58
GeyerPA-OVoytikETreitPVDollSKleinhempelANiuLet al. Plasma Proteome Profiling to detect and avoid sample-related biases in biomarker studies. EMBO Mol Med. (2019) 11(11):e10427. doi:Â 10.15252/emmm.201910427
59
YoussefOSarhadiVKArmengolGPiiriläPKnuuttilaAKnuutilaS. Exhaled breath condensate as a source of biomarkers for lung carcinomas. A focus on genetic and epigenetic markers-A mini-review. Genes Chromosomes Cancer. (2016) 55(12):905–14. doi: 10.1002/gcc.22399
60
KumarRGeorgeBCampbellMRVermaNPaulAMMelo-AlvimCet al. HER family in cancer progression: From discovery to 2020 and beyond. Adv Cancer Res. (2020) 147:109–60. doi: 10.1016/bs.acr.2020.04.001
61
HolbroTHynesNE. ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol. (2004) 44:195–217. doi: 10.1146/annurev.pharmtox.44.101802.121440
62
SharmaSVBellDWSettlemanJSettlemanDAHaberDA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. (2007) 7(3):169–81. doi: 10.1038/nrc2088
63
BagchiSYuanREnglemanEG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. (2021) 16:223–49. doi: 10.1146/annurev-pathol-042020-042741
64
PowlesTDuránIvan der HeijdenMSLoriotYVogelzangNJDe GiorgiUet al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. (2018) 391(10122):748–57. doi: 10.1016/S0140-6736(17)33297-X
65
HuangLJiangSShiYA-O. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). J Hematol Oncol. (2020) 13(1):143. doi:Â 10.1186/s13045-020-00977-0
66
SeegobinKMajeedUWiestNManochakianRLouYZhaoY. Immunotherapy in non-small cell lung cancer with actionable mutations other than EGFR. Front Oncol. (2021) 11:750657. doi:Â 10.3389/fonc.2021.750657
67
AntoniaSJLópez-MartinJABendellJOttPATaylorMEderJPet al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. (2016) 17(7):883–95. doi: 10.1016/S1470-2045(16)30098-5
68
PatnaikAKangSPRascoDPapadopoulosKPElassaiss-SchaapJBeeramMet al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. (2015) 21(19):4286–93. doi: 10.1158/1078-0432.CCR-14-2607
69
KellyRJGiacconeG. Lung cancer vaccines. Cancer J. (2011) 17(5):302–8. doi: 10.1097/PPO.0b013e318233e6b4
70
WangJZouZHXiaHLHeJXZhongNSTaoAL. Strengths and weaknesses of immunotherapy for advanced non-small-cell lung cancer: a meta-analysis of 12 randomized controlled trials. PLOS ONE. (2012) 7(3):e32695. doi:Â 10.1371/journal.pone.0032695
71
ChiuMArmstrongEJLJenningsVFooSCrespo-RodriguezEBozhanovaGet al. Combination therapy with oncolytic viruses and immune checkpoint inhibitors. Expert Opin Biol Ther. (2020) 20(6):635–52. doi: 10.1080/14712598.2020.1729351
72
MorenoPJiménez-JiménezCGarrido-RodrÃguezMCalderón-SantiagoMMolinaSLara-ChicaMet al. Metabolomic profiling of human lung tumor tissues - nucleotide metabolism as a candidate for therapeutic interventions and biomarkers. Mol Oncol. (2018) 12(10):1778–96. doi: 10.1002/1878-0261.12369
73
TonorezosESJonesLW. Energy balance and metabolism after cancer treatment. Semin Oncol. (2013) 40(6):745–56. doi: 10.1053/j.seminoncol.2013.09.011
74
AoyagiTTerracinaKPRazaAMatsubaraHTakabeK. Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol. (2015) 7(4):17–29. doi: 10.4251/wjgo.v7.i4.17
75
NomuraMMoritaMTanumaN. A metabolic vulnerability of small-cell lung cancer. Oncotarget. (2018) 9(64):32278–9. doi: 10.18632/oncotarget.25964
76
CarpentierJA-OPavlykIMukherjeeUHallPESzlosarekPW. Arginine deprivation in SCLC: mechanisms and perspectives for therapy. Lung Cancer: Targets Ther. (2022) 13:53–66. doi: 10.2147/LCTT.S335117
77
HallPEReadyNJohnstonABomalaskiJSVenhausRRSheaffMet al. Phase II study of arginine deprivation therapy with pegargiminase in patients with relapsed sensitive or refractory small-cell lung cancer. Clin Lung Cancer. (2020) 21(6):527–33. doi: 10.1016/j.cllc.2020.07.012
78
SzlosarekPWGrimshawMJWilbanksGDHagemannTWilsonJLBurkeFet al. Aberrant regulation of argininosuccinate synthetase by TNF-alpha in human epithelial ovarian cancer. Int J Cancer. (2007) 121(1):6–11. doi: 10.1002/ijc.22666
79
LongYTsaiWBWangpaichitrMTsukamotoTSavarajNFeunLGet al. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction. Mol Cancer Ther. (2013) 12(11):2581–90. doi: 10.1158/1535-7163.MCT-13-0302
80
SaxtonRASabatiniDM. mTOR signaling in growth, metabolism, and disease. Cell. (2017) 169(2):361–71. doi: 10.1016/j.cell.2017.02.004
81
StineZEWaltonZEAltmanBJHsiehALDangCV. MYC, metabolism, and cancer. Cancer Discov. (2015) 5(10):1024–39. doi: 10.1158/2159-8290.CD-15-0507
82
KrenczISebestyenAKhoorA. mTOR in lung neoplasms. Pathol Oncol Res. (2020) 26(1):35–48. doi: 10.1007/s12253-020-00796-1
83
ZhangPA-OXPeiSZhouGZhangMZhangLZhangZA-O. Purine metabolism in lung adenocarcinoma: A single-cell analysis revealing prognostic and immunotherapeutic insights. J Cell Mol Med. (2024) 28(8):e18284. doi:Â 10.1111/jcmm.18284
84
MaQA-OWangJRenYMengFZengL. Pathological mechanistic studies of osimertinib resistance in non-small-cell lung cancer cells using an integrative metabolomics-proteomics analysis. J Oncol. (2020) 2020:6249829. doi:Â 10.1155/2020/6249829
85
PanXChenWNieMLiuYXiaoZZhangYet al. A serum metabolomic study reveals changes in metabolites during the treatment of lung cancer-bearing mice with anlotinib. Cancer Manag Res. (2021) 13:6055–63. doi: 10.2147/CMAR.S300897
86
ZhangLCuiYMeiJZhangZZhangP.A.-O.X. Exploring cellular diversity in lung adenocarcinoma epithelium: Advancing prognostic methods and immunotherapeutic strategies. Cell Prolif. (2024) 30:e13703. doi:Â 10.1111/cpr.13703
87
WangHYangXSunYLiYDongYShanDet al. Synergistic effect of metformin and EGFR-TKI in the treatment of non-small cell lung cancer. Transl Cancer Res. (2020) 9(1):372–81. doi: 10.21037/tcr.2019.11.09
88
ReckMCarboneDPGarassinoMBarlesiF. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. (2021) 32(9):1101–10. doi: 10.1016/j.annonc.2021.06.001
89
CaoWA-OTangQZengJJinXZuLXuS. A review of biomarkers and their clinical impact in resected early-stage non-small-cell lung cancer. Cancers. (2023) 15(18):4561. doi:Â 10.3390/cancers15184561
90
NijhawanHPPrabhakarBMisraAYadavKS. Fragmented antibodies in non-small cell lung cancer: A novel nano-engineered delivery system for detection and treatment of cancer. Drug Discov Today. (2023) 28(11):103701. doi:Â 10.1016/j.drudis.2023.103701
91
OxnardGRArcilaMESimaCSRielyGJChmieleckiJKrisMGet al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. (2011) 17(6):1616-. doi:Â 10.1158/1078-0432.CCR-10-2692
92
WangZFRenSXLiWGaoGH. Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis. BMC Cancer. (2018) 18(1):148. doi:Â 10.1186/s12885-018-4075-5
93
YuHAArcilaMERekhtmanNSimaCSZakowskiMFPaoWet al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. (2013) 19(8):2240–7. doi: 10.1158/1078-0432.CCR-12-2246
94
RangachariDToCShpilskyJEVanderLaanPAKobayashiSSMushajiangMet al. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. J Thoracic Oncol. (2019) 14(11):1995–2002. doi: 10.1016/j.jtho.2019.07.016
95
TripathiSKBiswalBK. Allosteric mutant-selective fourth-generation EGFR inhibitors as an efficient combination therapeutic in the treatment of non-small cell lung carcinoma. Drug Discov Today. (2021) 26(6):1466–72. doi: 10.1016/j.drudis.2021.02.005
96
RenQZhangPLinHFengYChiHZhangXet al. A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts. Front Immunol. (2023) 14:1201573. doi:Â 10.3389/fimmu.2023.1201573
Summary
Keywords
lung cancer, immunotherapy, precision medicine, multi-omics, individualised therapy, immune checkpoints
Citation
Yan Y, Shen S, Li J, Su L, Wang B, Zhang J, Lu J, Luo H, Han P, Xu K, Shen X and Huang S (2024) Cross-omics strategies and personalised options for lung cancer immunotherapy. Front. Immunol. 15:1471409. doi: 10.3389/fimmu.2024.1471409
Received
27 July 2024
Accepted
30 August 2024
Published
25 September 2024
Volume
15 - 2024
Edited by
Wenyi Jin, City University of Hong Kong, Hong Kong SAR, China
Reviewed by
Qianhe Ren, Jiangsu University, China
Updates
Copyright
© 2024 Yan, Shen, Li, Su, Wang, Zhang, Lu, Luo, Han, Xu, Shen and Huang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ke Xu, cqghxuke@cqu.edu.cn; Xiang Shen, shenxiangdoctor@163.com; Shangke Huang, huangshangke001@swmu.edu.cn
†These authors have contributed equally to this work and share first authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.